Your search for apixaban returned 44 results

Portola Pharmaceuticals, Bristol-Myers Squibb Company, and Pfizer announced results from the Phase 3 ANNEXA-A (Andexanet Alfa a Novel Antidote to the Anticoagulant Effects of FXa Inhibitors – Apixaban) study with andexanet alfa as a reversal agent for Eliquis (apixaban).

Apixaban and rivaroxaban are both factor Xa inhibitors.

For patients in the Apixaban for Reduction of Stroke and Other Thromboembolic Complications in Atrial Fibrillation (ARISTOTLE) trial, the 5 mg twice daily dose of apixaban is beneficial and appropriate for those with one dose-reduction criterion, according to a study published online in JAMA Cardiology.

If Tybost is given with atazanavir or darunavir, coadministration with rivaroxaban is not recommended due to a potentially increased bleeding risk.

Findings from a study published in the British Journal of Clinical Pharmacology showed that apixaban appeared to be an appropriate alternative to warfarin for patients with severe renal impairment.

The Food and Drug Administration (FDA) has approved the first generics of Eliquis (apixaban; Bristol-Myers Squibb and Pfizer) tablets. Apixaban, a factor Xa inhibitor, is indicated: To reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation For the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism…

Andexxa, a recombinant modified human Factor Xa (FXa) protein, was approved under the FDA’s Accelerated Approval pathway.

Bristol-Myers Squibb and Pfizer announced that the FDA has acknowledged receipt of the New Drug Application (NDA) resubmission for Eliquis (apixaban) to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF).

To investigate the association between DOAC use and PPI initiation, researchers used data from community pharmacies in the Netherlands from 2012-2016.

Study findings revealed an increased risk of surgical intervention in women exposed to rivaroxaban.